Paper42495293
Integrating Experimental Physicochemical Data with PBPK Modeling to Guide the Translational Development of the Antifungal 1,3,4-Oxadiazole Derivative LMM6.
Piai JMB and 6 others. ACS Omega, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Integrating Experimental Physicochemical Data with PBPK Modeling to Guide the Translational Development of the Antifungal 1,3,4-Oxadiazole Derivative LMM6. Papers, record 42495293. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42495293
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Integrating Experimental Physicochemical Data with PBPK Modeling to Guide the Translational Development of the Antifungal 1,3,4-Oxadiazole Derivative LMM6.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References45
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23945604 | Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. | CPT Pharmacometrics Syst Pharmacol | 2013 | https://conductscience.org/library/papers/23945604 | PubMed |
| 2 | 26148672 | Quantitative and qualitative analysis of the novel antitumor 1,3,4-oxadiazole derivative (GLB) and its metabolites using HPLC-UV and UPLC-QTOF-MS. | Sci Rep | 2015 | https://conductscience.org/library/papers/26148672 | PubMed |
| 3 | 38003416 | The Interplay of Permeability, Metabolism, Transporters, and Dosing in Determining the Dynamics of the Tissue/Plasma Partition Coefficient and Volume of Distribution-A Theoretical Investigation Using Permeability-Limited, Physiologically Based Pharmacokinetic Modeling. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/38003416 | PubMed |
| 4 | 39664427 | Solubilization techniques used for poorly water-soluble drugs. | Acta Pharm Sin B | 2024 | https://conductscience.org/library/papers/39664427 | PubMed |
| 5 | 15893920 | Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds. | Eur J Pharm Biopharm | 2005 | https://conductscience.org/library/papers/15893920 | PubMed |
| 6 | 23738721 | Coupling biorelevant dissolution methods with physiologically based pharmacokinetic modelling to forecast in-vivo performance of solid oral dosage forms. | J Pharm Pharmacol | 2013 | https://conductscience.org/library/papers/23738721 | PubMed |
| 7 | 7617530 | A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. | Pharm Res | 1995 | https://conductscience.org/library/papers/7617530 | PubMed |
| 8 | 32533366 | Development and Validation of Sample Preparation and an HPLC Analytical Method for Dissolution Testing in Fed-State Simulated Gastric Fluid-Illustrating Its Application for Ibuprofen and Ketoconazole Immediate Release Tablets. | AAPS PharmSciTech | 2020 | https://conductscience.org/library/papers/32533366 | PubMed |
| 9 | 31010605 | Emerging and reemerging fungal infections. | Semin Diagn Pathol | 2019 | https://conductscience.org/library/papers/31010605 | PubMed |
| 10 | 39498820 | Global sensitivity analysis of Open Systems Pharmacology Suite physiologically based pharmacokinetic models. | CPT Pharmacometrics Syst Pharmacol | 2024 | https://conductscience.org/library/papers/39498820 | PubMed |
| 11 | 17372688 | Estimation of intragastric solubility of drugs: in what medium? | Pharm Res | 2007 | https://conductscience.org/library/papers/17372688 | PubMed |
| 12 | 23383426 | Strategies to address low drug solubility in discovery and development. | Pharmacol Rev | 2013 | https://conductscience.org/library/papers/23383426 | PubMed |
| 13 | 34176369 | Validating ADME QSAR Models Using Marketed Drugs. | SLAS Discov | 2021 | https://conductscience.org/library/papers/34176369 | PubMed |
| 14 | 33800117 | Fungicidal Activity of a Safe 1,3,4-Oxadiazole Derivative Against Candida albicans. | Pathogens | 2021 | https://conductscience.org/library/papers/33800117 | PubMed |
| 15 | 24396137 | Tissue penetration of antifungal agents. | Clin Microbiol Rev | 2014 | https://conductscience.org/library/papers/24396137 | PubMed |
| 16 | 36140156 | Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics. | Biomedicines | 2022 | https://conductscience.org/library/papers/36140156 | PubMed |
| 17 | 9487541 | Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. | Pharm Res | 1998 | https://conductscience.org/library/papers/9487541 | PubMed |
| 18 | 22391790 | The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs. | AAPS J | 2012 | https://conductscience.org/library/papers/22391790 | PubMed |
| 19 | 22830056 | Drug solubility: importance and enhancement techniques. | ISRN Pharm | 2012 | https://conductscience.org/library/papers/22830056 | PubMed |
| 20 | 31736369 | Is there enough focus on lipophilicity in drug discovery? | Expert Opin Drug Discov | 2020 | https://conductscience.org/library/papers/31736369 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42495293
GET https://conductscience.org/api/papers/v1/42495293/references?page=2